TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00182013
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open treatment with Risperidone
Study: NCT00182013
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open treatment with Olanzapine
Study: NCT00182013
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open treatment with Quetiapine
Study: NCT00628342
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg Oral tablet once daily
Study: NCT00628342
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg Oral tablet once daily
Study: NCT04601844
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered subcutaneously
Study: NCT04601844
Drug: Cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered SC
Study: NCT00074620
Drug: PEG-hirudin
Normalized name: PEG-Hirudin
DrugBank: Pegmusirudin (DB19220)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01767259
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan alone
Study: NCT01767259
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide alone
Study: NCT01026233
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg IV every 21 days
Study: NCT00005786
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01662180
Drug: Follicle Stimulating Hormone
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
Study: NCT02243813
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
Study: NCT05578313
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
Study: NCT02823236
Drug: Topical Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
Study: NCT02823236
Drug: Triamcinolone + Pirfenidone
Normalized name: Pirfenidone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
Study: NCT02606409
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
Study: NCT02606409
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation at a starting dose of 10-70 µg/kg/hour.
Study: NCT02823236
Drug: Intralesional Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
Study: NCT04298749
Drug: GX-P1 or Placebo (dose level 1)
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GX-P1 dose level 1 or placebo
Study: NCT04298749
Drug: GX-P1 or Placebo (dose level 2)
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GX-P1 dose level 2 or placebo
Study: NCT04298749
Drug: GX-P1 or Placebo (dose level 3)
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GX-P1 dose level 3 or placebo
Study: NCT01843023
Drug: Extended Release Naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naltrexone for extended release injectable suspension
Study: NCT04286529
Drug: Calcitriol capsules
Normalized name: Calcitriol Capsules
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25micrograms, taken daily for eight weeks, orally
Study: NCT02026778
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.
Study: NCT02026778
Drug: ondansetron-betahistine
Normalized name: betahistine
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.
Study: NCT01843023
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
Study: NCT00190723
Drug: Enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02598206
Drug: PF-04136309
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets.
Study: NCT00587678
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg daily
Study: NCT02240771
Drug: Oral chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count \& Platelet count would be monitored every 15 days
Study: NCT00982826
Drug: ABT-072
Normalized name: ABT-072
DrugBank: ABT-072 (DB15156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arms information for a detailed description.
Study: NCT01643382
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
Study: NCT01633541
Drug: AT-101
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive AT-101 40 mg orally two times a day.
Study: NCT01633541
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (Taxotere) 75 mg/m2
Study: NCT01633541
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2
Study: NCT01633541
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
Study: NCT03472326
Drug: GS-9131
Normalized name: GS 9137
DrugBank: GS-9191 (DB15084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03472326
Drug: BIC
Normalized name: Mobic
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT00135317
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00683735
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg once daily in the morning
Study: NCT00683735
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: up to 2000 mg/day
Study: NCT00414206
Drug: Mecamylamine
Normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02773485
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
Study: NCT00530738
Drug: Lipoplus
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v. fat emulsion for parenteral nutrition
Study: NCT00530738
Drug: Lipofundin MCT
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.V. fat emulsion for parenteral nutrition
Study: NCT02426736
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02426736
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03649165
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
Study: NCT00369577
Drug: Inhaled Loxapine 5 mg
Normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Staccato Loxapine 5 mg, single dose
Study: NCT00369577
Drug: Inhaled Loxapine 10 mg
Normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Staccato Loxapine 10 mg, single dose
Study: NCT03649165
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
Study: NCT02739035
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg of IV dexamethasone immediately before MUA.
Study: NCT00940992
Drug: DER 45 EV
Normalized name: Diäthylaminoäthanol ester der p-butylaminobenzösäure
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application to face for 12 weeks
Study: NCT01312337
Drug: salvage iressa
Normalized name: Iressa
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iressa 250mg per day until progression
Study: NCT03523091
Drug: OnabotulinumtoxinA 100Unit Injection
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Initial treatment with the option of repeat injections every 3 months
Study: NCT01126307
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg tid
Study: NCT03904199
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
Study: NCT04204837
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
Study: NCT04204837
Drug: Nivolumab plus Relatlimab
Normalized name: nivolumab / relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
Study: NCT01985061
Drug: BX2
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01985061
Drug: BX3
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01111903
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
Study: NCT02048709
Drug: GDC-0919
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
Study: NCT01712113
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01712113
Drug: Avapro
Normalized name: Avapro
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02294058
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules for oral administration once a day
Study: NCT02294058
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by intramuscular injection once a week
Study: NCT02294058
Drug: Placebo to ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Matching placebo capsules administered orally once a day
Study: NCT02294058
Drug: Placebo to interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo intramuscular injection once a week
Study: NCT00226382
Drug: Pegylated Interferon-alfa-2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegasys once weekly
Study: NCT01944319
Drug: Routine meropenem therapy
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
Study: NCT01944319
Drug: Meropenem therapy based on a PPK and PD model
Normalized name: meropenem and vaborbactam
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
Study: NCT04617067
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
Study: NCT04617067
Drug: Gemcitabine (GEM) and Nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
Study: NCT00657644
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
Study: NCT01547741
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01547741
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03476109
Drug: Randomisation to omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Study: NCT03476109
Drug: Randomisation to mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Study: NCT00006391
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006391
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02837237
Drug: KBP-5074
Normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.
Study: NCT01884896
Drug: Metoprolol Succinate ER Tablet 200 mg
Normalized name: metoprolol succinate Extended Release Oral Tablet
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 \* 200 mg tablet per day
Study: NCT02292719
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT02292719
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT04171050
Drug: Pudendal Nerve Block plus anesthesia
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthesia injections plus a pudendal nerve block
Study: NCT02538042
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
Study: NCT02538042
Drug: SPECTRUM Nicotine Research Cigarettes (0.07 mg)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
Study: NCT03663101
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
Study: NCT02842294
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03026881
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib either at 20,30,40mg twice daily,capsule oral.
Study: NCT03026881
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03026881
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection
Study: NCT02220829
Drug: Preventive administration of Rapaflo
Normalized name: Rapaflo
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
Study: NCT04328740
Drug: TP-1454 monotherapy
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Flat dose once or twice daily, alone